Hordeolum Clinical Trial
Official title:
Dose Antibiotic Need in Hordeolum After Incision and Curettage? : A Randomized, Placebo-controlled Trial
To compare the effectiveness of combined antibiotic ophthalmic solution (neomycin sulfate, polymyxin B sulfate and gramicidin) with placebo (artificial tear) in the treatment of hordeolum after incision and curettage
Status | Recruiting |
Enrollment | 120 |
Est. completion date | December 2008 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - at least 5-millimeters hordeolum - the onset within 7 days Exclusion Criteria: - previous incision and curettage of the same site within 1 month or more than 3 times - lesions in the adjacent areas suggesting of complications associated with hordeolum such as preseptal cellulitis or blepharitis - The patients with immunodeficiency, history of bleeding tendency - allergy to aminoglycoside, polymyxin B, gramicidin, xylocaine and povidone iodine |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Thailand | Department of Ophthalmology, Chulalongkorn University | Bangkok |
Lead Sponsor | Collaborator |
---|---|
Chulalongkorn University |
Thailand,
Hirunwiwatkul P, Wachirasereechai K. Effectiveness of combined antibiotic ophthalmic solution in the treatment of hordeolum after incision and curettage: a randomized, placebo-controlled trial: a pilot study. J Med Assoc Thai. 2005 May;88(5):647-50. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pain scale | 1,3,7 days after treatment | Yes | |
Secondary | Mass size and duration of cure | 1, 3, 7, 30 days after treatment | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00420628 -
Pediatric Zylet Safety and Efficacy Study
|
Phase 4 |